Ipca Laboratories, a Rs. 3.200 crore pharma major from Mumbai, has posted strong growth in bottom line during the fourth quarter ended March 2014 due to higher formulation exports. Its standalone net profit for the fourth quarter moved up by 81.7 per cent to Rs. 137.03 crore from Rs. 75.43 crore in the corresponding period of last year. Its standalone net sales increased by 12.3 per cent to Rs. 739.81 crore from Rs. 658.64 crore. With strong improvement in profits, its EPS improved to Rs. 10.86 from Rs. 5.98 in the last period.
The board of directors has recommended final dividend of 125 per cent for the year. Taking into the account interim dividend of 125 per cent paid earlier, the total dividend worked out to 250 per cent.
Ipca’s formulation sales increased by 15.9 per cent during the quarter under review to Rs. 569.74 crore from Rs. 491.46 crore and its API sales improved marginally to Rs. 170.07 crore from Rs. 167.18 crore. Export of formulations went up to Rs. 373.18 crore from Rs. 313.05 crore.
For the full year ended March 2014, Ipca’s consolidated net sales increased by 16.2 per cent to Rs. 3,199 crore from Rs. 2,754 crore in the previous year. Its net profit went up by 47.9 per cent to Rs. 478.54 crore from Rs. 323.55 crore. EBDITA margins improved to 24.89 per cent from 22.36 per cent in the previous year.
Its formulation sales improved by 17 per cent to Rs. 2,417 crore from Rs. 2,072 crore and API sales increased by 15 per cent to Rs. 765 crore from Rs. 667 crore. Formulation exports improved to Rs. 2,048 crore from Rs. 1,194 crore and domestic sales of formulation moved up 10 per cent to Rs. 969 crore from Rs. 878 crore. API exports improved by 15 per cent to Rs. 600 crore from Rs. 522 crore.